• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Bristol-Myers Squibb names three research project winners for in viral diseases

Bristol-Myers Squibb names three research project winners for in viral diseases

January 31, 2014
CenterWatch Staff

Three European virology researchers were awarded research grants this week based on their proposed research projects to investigate novel ways to cure viral diseases. The award-winners were chosen by an independent faculty as part of the Partnering for Cure Program, a first-of-its kind, Europe-wide initiative. The program, sponsored by Bristol-Myers Squibb, is designed to accelerate innovative scientific research that could lead to cure in viral diseases, namely HIV, hepatitis B (HBV) and hepatitis C (HCV).

Partnering for Cure was launched by a faculty of independent virology experts with the shared goals of supporting breakthrough research and facilitating greater collaboration and knowledge-sharing with the virology clinical community. It has been developed and led by a European faculty of independent virology experts from across Europe, including Germany, France, Switzerland, Sweden, Belgium, Italy, Spain and the U.K. with the support of Bristol-Myers Squibb R&D staff.

"While significant advances have been made in virology over recent years, there is more work to be done to be able one day to cure chronic infectious diseases such as HIV, HBV and HCV," said Christine Katlama, Partnering for Cure faculty chair, Hôpital Pitié-Salpêtrière, Paris. "The Partnering for Cure initiative is tackling this head-on, joining with the clinical community to support research that will bring us even closer to our ultimate hope of a potential 'cure'."

"We are proud to announce the selected investigators of the first Partnering for Cure research initiative," said George Hanna, M.D., vice president, HIV Development, Bristol-Myers Squibb. "Bristol-Myers Squibb has been a leader in virology for many years and we remain committed to supporting breakthrough research and education in virology with the goal of providing a forum for discussion of emerging science on the nature of chronic viral infections."

The winners of the research grants chosen in a blind evaluation by the Partnering for Cure Faculty are:

  • Matthieu Perreau, Center Hospitalier Universitaire Vaudois (CHUV) Service Immunologie et Allergie, Switzerland, for the identification of the memory CD4 T-cell population(s) harboring replication competent HIV-1 within lymphoid tissues
  • Ruxandra Calin, department of Infectious and Tropical Diseases, Hôpital Pitié-Salpêtrière, France, for the comprehensive analysis of HIV reservoirs in chronically infected HIV-1 treated patients with a low total cell-associated blood HIV-DNA
  • Valentina Svicher, AVIRALIA Foundation, Italy, for the identification and functional characterization of genetic elements in HBV genome correlated with HBV reactivation driven by immunosuppression

The objectives of Partnering for Cure are to provide medical education to physicians interested in virology, provide support to researchers active in virology and provide a forum for physicians and researchers to discuss advances in virology toward a cure.

The Partnering for Cure initiative reinforces Bristol-Myers Squibb's commitment in virology, which is rooted in the company's legacy in virology and ongoing research in HIV and viral hepatitis. Chronic viral infections make a substantial contribution to the burden of chronic diseases and premature mortality worldwide. In Dec. 2012, the Global Burden of Disease Study reported 1,465,000 deaths caused by HIV/AIDS and 1,445,000 deaths caused by viral hepatitis in 2010. Infections with hepatitis B and C viruses also cause an estimated 57% of cases of liver cirrhosis and 78% of cases of primary liver cancer annually. Whilst important advances have been made over the last decade, significant unmet needs and the opportunity for cure remains, particularly in HIV.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing